Real-World FASENRA study completed in korea: safety under the microscope
NCT ID NCT05091333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during routine medical care. The goal was to confirm known safety information and catch any new issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FASENRA (benralizumab)
What this could lead to
If results confirm safety, it supports continued use of FASENRA for controlling severe asthma and EGPA in real-world settings.
What could go wrong
This is a small, observational postmarketing study (51 people) with no control group, so it cannot prove cause and effect or detect rare side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE EOSINOPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Busan, South Korea
-
Research Site
Gangneung-si, South Korea
-
Research Site
Seoul, South Korea
-
Research Site
Suwon, South Korea
-
Research Site
Ulsan, South Korea